News and Announcements
Actinogen Medical US Roadshow Investor Presentation July 2016
- Published July 15, 2016 12:03PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
15th July 2016, ASX Announcement
Focusing on an innovative approach, through the inhibition of cortisol production, for treating cognitive impairment in chronic neurodegenerative and metabolic diseases
Xanamem™: A prime investment opportunity
- Alzheimer’s – a significant unmet need in a huge and growing global market
- Xanamem™’s innovative, differentiated mechanism of action targeting the stress hormone cortisol
- Evidence Xanamem™ is both symptomatic and disease modifying
- Phase II study funded through to completion
- Patent protected to 2031 – composition of matter
- Value enhancing additional indications in substantive markets of interest to big pharmaceutical companies – Alzheimers disease, Diabetes, Parkinson’s disease
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
